HLA-DQ2 peptide vaccine companion diagnostic - ImmusanTAlternative Names: Nexvax2 Diagnostic - ImmusanT
Latest Information Update: 17 May 2017
Price : $50
At a glance
- Originator ImmusanT
- Class Diagnostic agents
- Mechanism of Action
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I Coeliac disease
Most Recent Events
- 08 May 2017 Phase I development is ongoing in Coeliac disease (Diagnosis)
- 08 May 2017 Phase-I clinical trials in Coeliac disease (Diagnosis) (unspecified route) before May 2017 (ImmusanT company pipeline, May 2017).
- 16 Jul 2016 No recent reports of development identified for preclinical development in Coeliac disease(Diagnosis) in Australia